NanoViricides, Inc. Advances MPox Treatment Amid WHO’s Extended Global Health Emergency
NanoViricides, Inc. (NYSE American: NNVC), a leader in the development of host-mimetic nanomedicine, has reaffirmed its commitment to combating the MPox virus following the World Health Organization’s decision to extend the Public Health Emergency of International Concern (PHEIC). The company’s focus is on NV-387, a broad-spectrum antiviral drug that has successfully completed Phase I trials, […]